<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0603256995
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PREGADEX 150 MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PREGABALIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        123.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Pregadex contains the active substance pregabalin which belongs to a group of medicines used to treat epilepsy, neuropathic pain and Generalised Anxiety Disorder (GAD) in adults.</p><p><strong>Peripheral and central neuropathic pain: </strong>Pregadex is used to treat long lasting pain caused by damage to the nerves. A variety of diseases can cause peripheral neuropathic pain, such as diabetes or shingles. Pain sensations may be described as hot, burning, throbbing, shooting, stabbing, sharp, cramping, aching, tingling, numbness, pins and needles. Peripheral and central neuropathic pain may also be associated with mood changes, sleep disturbance, fatigue (tiredness), and can have an impact on physical and social functioning and overall quality of life.</p><p><strong>Epilepsy:</strong> Pregadex is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults. Your doctor will prescribe Pregadex for you to help treat your epilepsy when your current treatment is not controlling your condition. You should take Pregadex in addition to your current treatment. Pregadex is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment.</p><p><strong>Generalised Anxiety Disorder: </strong>Pregadex is used to treat Generalised Anxiety Disorder (GAD). The symptoms of GAD are prolonged excessive anxiety and worry that are difficult to control.</p><p>GAD can also cause restlessness or feeling keyed up or on edge, being easily fatigued (tired), having difficulty concentrating or mind going blank, feeling irritable, having muscle tension or sleep disturbance. This is different to the stresses and strains of everyday life.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Pregadex</strong></p><p>If you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Pregadex.</p><ul><li>&nbsp;Serious skin rashes including Stevens-Johnson syndrome, toxic epidermal necrolysis have been reported in association with pregabalin. Stop using pregabalin and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.</li><li><p>Some patients taking Pregadex have reported symptoms suggesting an allergic reaction. These symptoms include swelling of the face, lips, tongue, and throat, as well as diffuse skin rash. Should you experience any of these reactions, you should contact your physician immediately.</p></li><li><p>&nbsp;Pregadex has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in elderly patients. Therefore, you should be careful until you are used to any effect the medicine might have.</p></li><li><p>Pregadex may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. You should immediately tell your doctor if you experience any changes in your vision.</p></li><li><p>Some patients with diabetes who gain weight while taking pregabalin may need an alteration in their diabetic medicines.</p></li><li><p>&nbsp;Certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have similar side effects to Pregabalin and the severity of these effects may be increased when taken together.</p></li><li><p>There have been reports of heart failure in some patients when taking Pregadex; these patients were mostly elderly with cardiovascular conditions.<strong> Before taking this medicine you should tell your doctor if you have a history of heart disease.</strong></p></li><li><p>There have been reports of kidney failure in some patients when taking Pregadex. If while taking Pregadex you notice decreased urination, you should tell your doctor as stopping the medicine may improve this.</p></li><li><p>Some patients being treated with anti-epileptics such as Pregadex have had thoughts of harming or killing themselves or shown suicidal behaviour. If at any time you have these thoughts&nbsp;or shown such behaviour, immediately contact your doctor.</p></li><li><p>&nbsp;When Pregadex is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g., constipation, blocked or paralysed bowel). Tell your doctor if you experience constipation, especially if you are prone to this problem.</p></li><li><p>&nbsp;Before taking this medicine you should tell your doctor if you have a history of alcoholism or any drug abuse or dependence. Do not take more medicine than prescribed.</p></li><li><p>&nbsp;There have been reports of convulsions when taking Pregadex or shortly after stopping Pregadex. If you experience a convulsion, contact your doctor immediately.</p></li><li><p>There have been reports of reduction in brain function (encephalopathy) in some patients taking Pregadex when they have other conditions. Tell your doctor if you have a history of any serious medical conditions, including liver or kidney disease.</p></li><li><p>There have been reports of breathing difficulties. If you have nervous system disorders, respiratory disorders, renal impairment, or you are older than 65, your doctor may prescribe you a different dosing regimen. Contact your doctor if you experience trouble breathing or shallow breaths.</p></li></ul><p><strong>Children and adolescents</strong></p><p>The safety and efficacy in children and adolescents (under 18 years of age) has not been established and therefore, pregabalin should not be used in this age group.</p><p><strong>Other medicines and Pregadex</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Pregadex and certain other medicines may influence each other (interaction). When taken with certain other medicines, which have sedative effects (including opioids), Pregadex may potentiate these effects and could lead to respiratory failure, coma and death. The degree of dizziness, sleepiness and decreased concentration may be increased if Pregadex is taken together with medicinal products containing:</p><p>&bull; Oxycodone &ndash; (used as a pain-killer)</p><p>&bull; Lorazepam &ndash; (used for treating anxiety)</p><p>&bull; Alcohol</p><p>Pregadex may be taken with oral contraceptives.</p><p><strong>Pregadex with food, drink and alcohol</strong></p><p>Pregadex capsules may be taken with or without food. It is advised not to drink alcohol while taking Pregadex.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Pregadex should not be taken during pregnancy or when breast-feeding, unless you are told otherwise by your doctor. Pregabalin use during the first 3 months of pregnancy may cause birth defects in the unborn child that require medical treatment. In a study reviewing data from women in Nordic countries who took pregabalin in the first 3 months of pregnancy, 6 babies in every 100 had such birth defects. This compares to 4 babies in every 100 born to women not treated with pregabalin in the study. Abnormalities of the face (orofacial clefts), the eyes, the nervous system (including the brain), kidneys and genitals have been reported. Effective contraception must be used by women of childbearing potential. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine</p><p><strong>Driving and using machines </strong></p><p>Pregadex may produce dizziness, sleepiness and decreased concentration. You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities.</p><p><strong>Lactose intolerance </strong></p><p>Pregadex contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will determine what dose is appropriate for you. Pregadex is for oral use only</p><p><strong>Peripheral and central neuropathic pain, epilepsy or Generalised Anxiety Disorder:</strong></p><p>&bull; Take the number of capsules as instructed by your doctor.</p><p>&bull; The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day.</p><p>&bull; Your doctor will tell you to take Pregadex either twice or three times a day. For twice a day take Pregadex once in the morning and once in the evening, at about the same time each day. For three times a day take Pregadex once in the morning, once in the afternoon and once in the evening, at about the same time each day.</p><p>&nbsp;</p><p>If you have the impression that the effect of Pregadex is too strong or too weak, talk to your doctor or pharmacist.</p><p>If you are an older patient (over 65 years of age), you should take Pregadex normally except if you have problems with your kidneys.</p><p>Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.</p><p>Swallow the capsule whole with water.</p><p>Continue taking Pregadex until your doctor tells you to stop.</p><p>&nbsp;</p><p><strong>If you take more Pregadex than you should </strong></p><p>Call your doctor or go to the nearest hospital emergency unit immediately. Take your box or bottle of Pregadex capsules with you. You may feel sleepy, confused, agitated, or restless as a result of&nbsp;taking more Pregadex than you should. Fits have also been reported.</p><p><strong>If you forget to take Pregadex </strong></p><p>It is important to take yourPregadex capsules regularly at the same time each day. If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. In that case, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Pregadex </strong></p><p>Do not stop taking Pregadex unless your doctor tells you to. If your treatment is stopped it should be done gradually over a minimum of 1 week.</p><p>After stopping long and short-term Pregadex treatment, you need to know that you may experience certain side effects. These include, trouble sleeping, headache, nausea, feeling anxious, diarrhoea, flu-like symptoms, convulsions, nervousness, depression, pain, sweating, and dizziness. These symptoms may occur more commonly or severely if you have been taking Pregadex for a longer period of time.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><p>&bull; Dizziness, drowsiness, headache</p><p><strong>Common: may affect up to 1 in 10 people </strong></p><p>&bull; Increased appetite</p><p>&bull; Feeling of elation, confusion, disorientation, decrease in sexual interest, irritability</p><p>&bull; Disturbance in attention, clumsiness, memory impairment, loss of memory, tremor, difficulty with speaking, tingling feeling, numbness, sedation, lethargy, insomnia, fatigue, feeling abnormal</p><p>&bull; Blurred vision, double vision</p><p>&bull; Vertigo, problems with balance, fall</p><p>&bull; Dry mouth, constipation, vomiting, flatulence, diarrhoea, nausea, swollen abdomen</p><p>&bull; Difficulties with erection</p><p>&bull; Swelling of the body including extremities</p><p>&bull; Feeling drunk, abnormal style of walking</p><p>&bull; Weight gain</p><p>&bull; Muscle cramp, joint pain, back pain, pain in limb</p><p>&bull; Sore throat</p><p><strong>Uncommon: may affect up to 1 in 100 people </strong></p><p>&bull; Loss of appetite, weight loss, low blood sugar, high blood sugar</p><p>&bull; Change in perception of self, restlessness, depression, agitation, mood swings, difficulty finding words, hallucinations, abnormal dreams, panic attacks, apathy, aggression, elevated mood, mental impairment, difficulty with thinking, increase in sexual interest, problems with sexual functioning including inability to achieve a sexual climax, delayed ejaculation</p><p>&bull; Changes in eyesight, unusual eye movement, changes in vision including tunnel vision, flashes of light, jerky movements, reduced reflexes, increased activity, dizziness on standing,sensitive skin, loss of taste, burning sensation, tremor on movement, decreased consciousness, loss of consciousness, fainting, increased sensitivity to noise, feeling unwell</p><p>&bull; Dry eyes, eye swelling, eye pain, weak eyes, watery eyes, eye irritation</p><p>&bull; Heart rhythm disturbances, increased heart rate, low blood pressure, high blood pressure, changes in heart beat, heart failure</p><p>&bull; Flushing, hot flushes</p><p>&bull; Difficulty breathing, dry nose, nasal congestion</p><p>&bull; Increased saliva production, heartburn, numb around mouth</p><p>&bull; Sweating, rash, chills, fever</p><p>&bull; Muscle twitching, joint swelling, muscle stiffness, pain including muscle pain, neck pain</p><p>&bull; Breast pain</p><p>&bull; Difficulty with or painful urination, incontinence</p><p>&bull; Weakness, thirst, chest tightness</p><p>&bull; Changes in blood and liver test results (blood creatinine phosphokinase increased, alanine aminotransferase increased, aspartate aminotransferase increased, platelet count decreased, neutropenia, increase in blood creatinine, decrease in blood potassium)</p><p>&bull; Hypersensitivity, swollen face, itchiness, hives, runny nose, nose bleed, cough, snoring</p><p>&bull; Painful menstrual periods</p><p>&bull; Coldness of hands and feet</p><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people </strong></p><p>&bull; Abnormal sense of smell, swinging vision, altered perception of depth, visual brightness, vision loss</p><p>&bull; Dilated pupils, cross eyes</p><p>&bull; Cold sweat, tightness of the throat, swollen tongue</p><p>&bull; Inflammation of the pancreas</p><p>&bull; Difficulty in swallowing</p><p>&bull; Slow or reduced movement of the body</p><p>&bull; Difficulty with writing properly</p><p>&bull; Increased fluid in the abdomen</p><p>&bull; Fluid in the lungs</p><p>&bull; Convulsions</p><p>&bull; Changes in the recording of electrical changes (ECG) in the heart which correspond to heart rhythm disturbances</p><p>&bull; Muscle damage</p><p>&bull; Breast discharge, abnormal breast growth, breast growth in males</p><p>&bull; Interrupted menstrual periods</p><p>&bull; Kidney failure, reduced urine volume, urinary retention</p><p>&bull; Decrease in white blood cell count</p><p>&bull; Inappropriate behaviour, suicidal behaviour, suicidal thoughts.</p><p>&bull; Allergic reactions which may include difficulty breathing, inflammation of the eyes (keratitis) and a serious skin reaction characterised by reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals&nbsp;and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (StevensJohnson syndrome, toxic epidermal necrolysis).</p><p>&bull; Jaundice (yellowing of the skin and eyes)</p><p>&bull; Parkinsonism, that is symptoms resembling Parkinson&rsquo;s disease, such as tremor, bradykinesia (decreased ability to move), and rigidity (muscle stiffness).</p><p><strong>Very rare: may affecr up to 1 in 10,000 people</strong></p><p>&bull; Liver failure.</p><p>&bull; Hepatitis (inflammation of the liver).</p><p><strong>If you experience swollen face or tongue or if your skin turns red and starts to blister or peel, you should seek immediate medical advice.</strong></p><p>Certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have similar side effects to Pregabalin and the severity of these effects may be increased when taken together. The following side effects were reported in the postmarketing experience: trouble breathing, shallow breaths.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Store Below 30&ordm;C.</p><p>&bull; Do not use this medicine after the expiry date which is stated on the carton and the pack label after EXP. The expiry date refers to the last day of that month.</p><p>&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance:</strong> pregabalin. Each hard capsule contains 75 mg, 150 mg or 300 mg pregabalin.</p><p><strong>The other ingredients</strong>: Lactose NF Fast Flow, Starch (1500), Purified Talc, Gelatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pregadex 75 mg capsule is size no. 3, hard gelatin capsule with opaque light yellow to yellow cap
and body containing a white to off white powder. The capsule is printed with “PREGADEX 75mg”
on the both parts.
Pregadex 150 mg capsule is size no. 2, hard gelatin capsule with opaque orange cap and body
containing a white to off white powder. The capsule is printed with “PREGADEX 150mg” on the
both parts.
Pregadex 300 mg capsule is size no. "0el" hard gelatin capsule with opaque light brown cap and
body containing a white to off white powder. The capsule is printed with “PREGADEX 300mg”
on the both parts.
Each pack contains 30 capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SPIMACO&nbsp;</strong></p><p>Al-Qassim pharmaceutical plant&nbsp;</p><p>Saudi Arabia&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 November 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بريجاديكس على المادة الفعالة بريجابالين التي تنتمي إلى مجموعة من الأدوية المستخدمة لعلاج الصرع وآلام الأعصاب واضطراب القلق العام لدى البالغين.</p><p dir="RTL"><strong>آلام الأعصاب الطرفية والمركزية: يستخدم </strong>بريجاديكس لعلاج الألم طويل الأمد الناجم عن تلف الأعصاب. يمكن أن تسبب مجموعة متنوعة من الأمراض ألم الاعتلال العصبي المحيطي، مثل مرض السكري أو القوباء المنطقية.يمكن وصف أحاسيس الألم بأنها سخونة، وحرق، ونابض، وطلق، وطعن، حاد، تشنج، ألم، وخز، خدر، دبابيس وإبر. قد يرتبط ألم الأعصاب المحيطية والمركزية أيضا بتغيرات المزاج واضطراب النوم والتعب ويمكن أن يكون له تأثير على الأداء البدني والاجتماعي ونوعية الحياة بشكل عام.</p><p dir="RTL"><strong>الصرع</strong>: يستخدم بريجاديكس لعلاج شكل معين من الصرع (نوبات صرع جزئية مع أو بدون تعميم ثانوي) في البالغين. سيصف لك طبيبك بريجاديكس للمساعدة في علاج الصرع عندما لا يتحكم علاجك الحالي في حالتك. يجب أن تأخذ بريجاديكس بالإضافة إلى علاجك الحالي. إن بريجاديكس لا يصرف وحده كعلاج لهذه الحالات، بل يتوجب دائما تناوله بمصاحبة أدوية علاج نوبات الصرع الأخرى</p><p dir="RTL"><strong>اضطراب القلق المتعمم&nbsp;</strong>: كما إن بريجاديكس يوصف كعلاج لحالات اضطرابات القلق المتعمم. تتمثل أعراض اضطرابات القلق المتعمم بزيادة القلق والتوتر واستمراره لفترات طويلة يصعب السيطرة عليها. كما أن اضطرابات القلق المتعمم قد تسبب أيضا&nbsp;التململ والإحساس بالضيق أو العصبية، الشعور بالتعب و الإرهاق بسهولة، صعوبة التركيز أو النسيان، سرعة التهيج، وجود تشنج عضلي أو عدم انتظام النوم. وهذه الأعراض تختلف عن الضغوط والتوترات الناتجة عن الحياة اليومية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول بريجاديكس</strong></p><p>إذا كان لديك حساسية من بريجابالين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p><strong>التحذيرات والاحتياطات</strong></p><p>تحدث إلى طبيبك أو الصيدلي قبل تناول بريجاديكس.</p><p>&bull; تم الإبلاغ عن طفح جلدي خطير بما في ذلك متلازمة ستيفنز جونسون، وانحلال البشرة السام مع بريجابالين. توقف عن استخدام بريجابالين واطلب العناية الطبية على الفور إذا لاحظت أيا من الأعراض المتعلقة بهذه التفاعلات الجلدية الخطيرة الموضحة في القسم .4</p><p>&bull; أبلغ بعض المرضى الذين يتناولون بريجاديكس عن أعراض تشير إلى رد فعل تحسسي. وتشمل هذه الأعراض تورم الوجه والشفتين واللسان والحلق، وايضا طفح جلدي منتشر. إذا واجهت أيا من هذه الأعراض، يجب عليك الاتصال بطبيبك على الفور.</p><p>&bull; قد يصاحب تناول بريجاديكس شعور بالدوخة والنعاس والتي قد تزيد من احتمالية الإصابة نتيجة السقوط في حالة المرضى كبار السن. لذلك يجب أن تتوخى الحذر لحين التعود على أي تأثير قد يصاحب هذا الدواء.</p><p>&bull; قد يسبب بريجاديكس ضبابية أو فقدان الرؤية، أو تغييرات أخرى في البصر، وكثير منها مؤقت. يجب عليك إخبار طبيبك على الفور إذا واجهت أي تغييرات في رؤيتك.</p><p>&bull; في حالة بعض مرضى السكري الذين قد تحدث زيادة في الوزن لديهم نتيجة تناول بريجاديكس قد يحتاجون إلى إجراء تعديل في أدويتهم المخفضة للسكر في الدم.</p><p>&bull; قد تزداد احتمالية ظهور بعض الأعراض الجانبية مثل النعاس في حالة المرضى الذين يعانون من إصابات في النخاع الشوكي بسبب تناولهم أدوية أخرى مثل مضادات الألم والتشنج، التي تكون تأثيراتها الجانبية مماثلة وشدة هذه الأعراض قد تزداد عند تناول هذه الادوية مع بريجاديكس</p><p>&bull; هناك تقارير عن حدوث قصور في القلب لدى بعض المرضى عند تناول بريجاديكس؛ كان هؤلاء المرضى في الغالب من كبار السن الذين يعانون من أمراض القلب والأوعية الدموية. <strong>قبل تناول هذا الدواء،يجب عليك إخبار طبيبك إذا كان لديك تاريخ من أمراض القلب.</strong></p><p>&bull; هناك تقارير عن حدوث فشل كلوي في بعض المرضى عند تناول بريجاديكس. إذا لاحظت أثناء تناول بريجاديكس انخفاضا في التبول، فيجب عليك إخبار طبيبك لأن إيقاف الدواء قد يحسن ذلك.</p><p>&bull; بعض المرضى الذين يعالجون بمضادات الصرع مثل بريجاديكس لديهم أفكار لإيذاء أو قتل أنفسهم أو أظهروا سلوكا انتحاريا. إذا كانت لديك هذه الأفكار في أي وقت أو أظهرت مثل هذا السلوك، فاتصل بطبيبك على الفور.</p><p>&bull; عندما يؤخذ بريجاديكس مع أدوية أخرى قد تسبب الإمساك (مثل بعض أنواع أدوية الألم)، فمن الممكن أن تحدث مشاكل في الجهاز الهضمي (على سبيل المثال، الإمساك، انسداد أو شلل الأمعاء). أخبر طبيبك إذا كنت تعاني من الإمساك، خاصة إذا كنت عرضة لهذه المشكلة.</p><p>&bull; قبل تناول هذا الدواء، يجب أن تخبر طبيبك إذا كان لديك تاريخ من إدمان الكحول أو أي تعاطي للمخدرات أو الاعتماد عليها. لا تأخذ أدوية أكثر مما هو موصوف.</p><p>&bull; هناك تقارير عن حدوث تشنجات عند تناول بريجاديكس أو بعد فترة وجيزة من إيقاف بريجاديكس. إذا كنت تعاني من تشنج، فاتصل بطبيبك على الفور.</p><p>&bull; هناك تقارير عن انخفاض في وظائف الدماغ (اعتلال الدماغ) في بعض المرضى الذين يتناولون بريجاديكس عندمايكون لديهم حالات مرضية أخرى. أخبر طبيبك إذا كان لديك تاريخ من أي حالات طبية خطيرة، بما في ذلك أمراض الكبد أو الكلى.</p><p>&bull; هناك تقارير عن صعوبات في التنفس. إذا كنت تعاني من اضطرابات في الجهاز العصبي أو اضطرابات في الجهاز التنفسي أو اختلال كلوي أو يزيد عمرك عن 65 عاما، فقد يصف لك طبيبك نظاما مختلفا للجرعات. اتصل بطبيبك إذا كنت&nbsp;تعاني من صعوبة في التنفس أو أنفاس ضحلة.</p><p><strong>الأطفال والمراهقون</strong></p><p>لم يتم إثبات السلامة والفعالية لدى الأطفال والمراهقين (دون سن 18 عاما) ، وبالتالي ، لا ينبغي استخدام بريجابالين في هذه الفئة العمرية.</p><p><strong>أدوية أخرى و بريجاديكس</strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أو قد تتناول أي أدوية أخرى. قديؤثر بريجاديكس وبعض الأدوية الأخرى على بعضها البعض (تداخلات دوائية). عند تناوله مع بعض الأدوية الأخرى، التي لها آثار مهدئة (بما في ذلك المواد الأفيونية)، قد يحفز بريجاديكس هذه الآثار ويمكن أن يؤدي إلى فشل الجهاز التنفسي والغيبوبة والوفاة. يمكن زيادة درجة الدوخة والنعاس وانخفاض التركيز إذا تم تناول بريجاديكس مع المنتجات الطبية التي تحتوي على:</p><p>&bull; أوكسيكودون &ndash; (يستخدم كمسكن للألم)</p><p>&bull; لورازيبام &ndash; (يستخدم لعلاج القلق)</p><p>&bull; الكحول</p><p>يمكن استخدام بريجاديكس بشكل متزامن مع أدوية منع الحمل التي يتم إعطاءها عن طريق الفم.</p><p><strong>بريجاديكس مع الطعام والشراب والكحول</strong></p><p>يمكن تناول كبسولات بريجاديكس مع الطعام أو بدونه. ينصح بعدم شرب الكحول أثناء تناول بريجاديكس.</p><p><strong>الحمل والرضاعة الطبيعية </strong></p><p>لا ينبغي أن يتم تناول بريجاديكس أثناء الحمل أو عند الرضاعة الطبيعية، ما لم يخبرك طبيبك بخلاف ذلك. استخدام بريجابالين خلال الأشهر ال 3 الأولى من الحمل قد يسبب تشوهات خلقية في الطفل الذي لم يولد بعد والتي تتطلب العلاج الطبي. في دراسة تستعرض بيانات من النساء في بلدان الشمال الأوروبي اللواتي تناولن بريجابالين في الأشهر الثلاثة الأولى من الحمل ، كان لدى 6 أطفال من كل 100 مثل هذه العيوب الخلقية. هذا بالمقارنة مع 4 أطفال من كل 100 مولود لنساء لم يعالجن بالبريجابالين في الدراسة. تم الإبلاغ عن تشوهات في الوجه (الشقوق الفموية الوجهية) والعينين والجهاز العصبي (بما في ذلك الدماغ) والكلى والأعضاء التناسلية. ويجب أن تستخدم النساء ذوات القدرة على الإنجاب وسائل منع الحمل الفعالة. إذا كنت حاملا أو مرضعة، أو تعتقدين أنك قد تكونين حاملا أو تخططين لإنجاب طفل، فاطلبي من طبيبك أو الصيدلي المشورة قبل تناول هذا الدواء.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p>قد ينتج عن بريجاديكس الدوخة والنعاس وانخفاض التركيز. يجب عليك عدم القيادة أو تشغيل الآلات المعقدة أو الانخراط في أنشطة أخرى يحتمل أن تكون خطرة حتى تعرف ما إذا كان هذا الدواء يؤثر على قدرتك على أداء هذه الأنشطة.</p><p><strong>عدم تحمل اللاكتوز</strong></p><p>يحتوي بريجاديكس على اللاكتوز مونوهيدرات. المرضى الذين يعانون من مشاكل وراثية نادرة من عدم تحمل الجالاكتوز أو نقص اللاكتاز أو سوء امتصاص الجلوكوز والجالاكتوز يجب ألا يأخذوا هذا الدواء</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول هذا الدواء تماما كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا. سيحدد طبيبك الجرعة المناسبة لك. بريجاديكس يستخدم عن طريق الفم فقط.</p><p><strong>ألم الاعصاب المحيطية والمركزية او الصرع او اضطراب القلق العام :&nbsp;&nbsp;</strong></p><ul><li>تناول عدد الكبسولات وفقا لتعليمات طبيبك .</li><li>إن الجرعة سيتم تحديدها بما يتناسب مع حالتك وتتراوح عادة بين&nbsp;150&nbsp;ملجم و&nbsp;600&nbsp;ملجم يوميا.&nbsp;</li><li>سخبرك طبيبك&nbsp;بتتناول بريجاديكس إما مرتين أو ثلاث مرات في اليوم . فى حالة مرتين في اليوم تناول بريجاديكس مرة واحدة في الصباح ومرة واحدة في المساء، في نفس الوقت تقريبا كل يوم. فى حالة ثلاث مرات في اليوم، خذ بريجاديكس مرة واحدة في الصباح، مرة واحدة في فترة ما بعد الظهر ومرة واحدة في المساء، في نفس الوقت تقريبا كل يوم.</li></ul><p>إذا شعرت أن تأثير بريجاديكس أقوى أو أضعف من المطلوب، أخبر طبيبك أو الصيدلي.&nbsp;</p><p>إذا كنت مريضا كبيرا في السن (أكبر من&nbsp;65&nbsp;سنة)، فيجب أن تأخذ بريجاديكس بشكل طبيعي إلا إذا كنت تعاني من مشاكل في كليتيك. قد يصف طبيبك جدولا زمنيا مختلفا للجرعات و / أو جرعة مختلفة إذا كنت تعاني من مشاكل في كليتيك. ابتلع الكبسولة بأكملها بالماء. استمر في تناول بريجاديكس حتى يخبرك طبيبك بالتوقف.</p><p><strong>إذا تناولت بريجاديكس أكثر مما ينبغي</strong></p><p>اتصل بطبيبك أو اذهب إلى أقرب وحدة طوارئ في المستشفى على الفور. خذ عبوة بريجاديكس معك. قد تشعر بالنعاس أو الارتباك أو الهياج أو القلق نتيجة تناول بريجاديكس أكثر مما ينبغي. كما تم الإبلاغ عن نوبات.</p><p>&nbsp;</p><p><strong>إذا نسيت أن تتناول بريجاديكس</strong></p><p>من المهم أن تأخذ كبسولات بريجاديكس بانتظام في نفس الوقت كل يوم. إذا نسيت تناول جرعة ، فتناولها بمجرد أن تتذكر ما لم يحين الوقت للجرعة التالية. في هذه الحالة ، ما عليك سوى الاستمرار في الجرعة التالية كالمعتاد. لا تأخذ جرعة مضاعفة للتعويض عن جرعة منسية.</p><p>&nbsp;</p><p><strong>إذا توقفت عن تناول بريجاديكس </strong></p><p>لا تتوقف عن تناول بريجاديكس ما لم يخبرك طبيبك بذلك. إذا تم إيقاف العلاج الخاص بك يجب أن يتم ذلك تدريجيا على مدى ما لايقل عن أسبوع. بعد التوقف عن علاج بريجاديكس على المدى الطويل والقصير، تحتاج إلى معرفة أنك قد تواجه بعض الآثار الجانبية. وتشمل هذه ، صعوبة في النوم ، والصداع ، والغثيان ، والشعور بالقلق ، والإسهال ، والأعراض الشبيهة بالإنفلونزا ، والتشنجات ، والعصبية ، والاكتئاب ، والألم ، والتعرق ، والدوخة. قد تحدث هذه الأعراض بشكل أكثر شيوعا أو شدة إذا كنت تتناول بريجاديكس لفترة أطول من الزمن. إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية ، یمكن أن يسبب هذا الدواء آثارا جانبية ، على الرغم من عدم تعرض الجميع لها</p><p><strong>شائع جدا: قد يؤثر على أكثر من 1 من كل 10 أشخاص </strong></p><p>&bull; الدوخة والنعاس والصداع</p><p><strong>شائع: قد يؤثر على ما يصل إلى 1 من كل 10 أشخاص</strong></p><p>&bull; زيادة الشهية</p><p>&bull; الشعور بالنشوة والارتباك والتوهان وانخفاض الاهتمام الجنسي والتهيج</p><p>&bull; اضطراب في الانتباه، والحماقة، وضعف الذاكرة، الذاكرة، وفقدان الرعاش، وصعوبة في التحدث، والشعور بالوخز، والخدر، والتخدير، والخمول، والأرق، والتعب، والشعور غير الطبيعي</p><p>&bull; عدم وضوح الرؤية، الرؤية المزدوجة</p><p>&bull; الدوار ، مشاكل في التوازن ، السقوط</p><p>&bull; جفاف الفم، والإمساك، والقيء، وانتفاخ البطن، والإسهال، والغثيان، وتورم البطن</p><p>&bull; صعوبات في الانتصاب</p><p>&bull; تورم الجسم بما في ذلك الأطراف</p><p>&bull; شعور بالثملة في حال سكر، أسلوب غير طبيعي فى المشي</p><p>&bull; زيادة الوزن</p><p>&bull; تشنج العضلات، آلام المفاصل، آلام الظهر، ألم في الأطراف</p><p>&bull; التهاب الحلق</p><p><strong>غير شائع: قد يؤثر على ما يصل إلى 1 من كل 100 شخص</strong></p><p>&bull; فقدان الشهية، وفقدان الوزن، وانخفاض نسبة السكر في الدم، وارتفاع نسبة السكر في الدم</p><p>&bull; تغير في إدراك الذات، والأرق، والاكتئاب، والإثارة، وتقلب المزاج، وصعوبة العثور على الكلمات، والهلوسة، والأحلام غير الطبيعية، الهلع،ونوبات واللامبالاة، والعدوان، والمزاج المرتفع، والضعف العقلي، وصعوبة التفكير، وزيادة الاهتمام الجنسي، ومشاكل في الأداء الجنسي بما في ذلك عدم القدرة على تحقيق نشوة جنسية، وتأخر القذف.</p><p>&bull; تغيرات في البصر، حركة العين غير العادية، تغيرات في الرؤية بما في ذلك رؤية نفقية، ومضات من الضوء، حركات متشنجة، انخفاض ردود الفعل، زيادة النشاط، الدوخة عند الوقوف، البشرة الحساسة، التذوق،فقدان حرقان، رعشة في الحركة، انخفاض الوعي، فقدان الوعي، الإغماء، زيادة الحساسية للضوضاء، الشعور بتوعك</p><p>&bull; جفاف العين، تورم العين، ألم العين، ضعف العينين، عيون دامعة، تهيج العين</p><p>&bull; اضطرابات ضربات القلب، وزيادة معدل ضربات القلب، وانخفاض ضغط الدم، وارتفاع ضغط الدم، والتغيرات في ضربات القلب، وفشل القلب</p><p>&bull; احمرار الوجه، توردات ساخنة.</p><p>&bull; صعوبة في التنفس وجفاف الأنف واحتقان الأنف</p><p>&bull; زيادة إنتاج اللعاب وحرقة المعدة والخدر حول الفم</p><p>&bull; التعرق والطفح الجلدي والقشعريرة والحمى</p><p>&bull; ارتعاش العضلات، وتورم المفاصل، وتصلب العضلات، والألم بما في ذلك آلام العضلات، وآلام الرقبة</p><p>&bull; ألم الثدي</p><p>&bull; صعوبة في التبول أو الألم أو سلس البول</p><p>&bull; الضعف والعطش وضيق الصدر</p><p>&bull; التغيرات في نتائج اختبار الدم والكبد (زيادة فوسفوكيناز الكرياتينين في الدم ، وزيادة ألانين أمينوترانسفيراز ، وزيادة أمينوترانسفيراز الأسبارتات ، وانخفاض عدد الصفائح الدموية ، وقلة العدلات ، وزيادة في الكرياتينين في الدم ، وانخفاض في البوتاسيوم في الدم)</p><p>&bull; الحساسية،فرط تورم الوجه، الحكة، الشري، الأنف،سيلان نزيف الأنف، السعال، الشخير</p><p>&bull; فترات الحيض المؤلمة</p><p>&bull; برودة اليدين والقدمين</p><p><strong>نادر: قد يؤثر على ما يصل إلى 1 من كل 1000 شخص</strong></p><p>&bull; حاسة الشم غير الطبيعية ، الرؤية المتأرجحة ، الإدراك المتغير للعمق ، السطوع البصري ، فقدان البصر</p><p>&bull; توسع الحدقة، حول العينان</p><p>&bull; عرق بارد، ضيق في الحلق، تورم اللسان</p><p>&bull; التهاب البنكرياس</p><p>&bull; صعوبة في البلع</p><p>&bull; بطء أو انخفاض حركة الجسم</p><p>&bull; صعوبة في الكتابة بشكل صحیح</p><p>&bull; زيادة السوائل في البطن</p><p>&bull; السوائل في الرئتين</p><p>&bull; التشنجات</p><p>&bull; التغيرات في تسجيل التغيرات الكهربائية ( تخطیط القلب) في القلب والتي تتوافق مع اضطرابات ضربات القلب</p><p>&bull; تلف العضلات</p><p>&bull; إفرازات الثدي ، نمو الثدي غير الطبيعي ، نمو الثدي عند الذكور</p><p>&bull; انقطاع الدورة الشهرية</p><p>&bull; الفشل الكلوي، وانخفاض حجم البول، واحتباس البول</p><p>&bull; انخفاض في عدد خلايا الدم البیضاء</p><p>&bull; السلوك غير اللائق ، السلوك الانتحاري ، الأفكار الانتحارية.</p><p>&bull; ردود الفعل التحسسية التي قد تشمل صعوبة في التنفس والتهاب العينين (التهاب القرنية) ورد فعل جلدي خطير يتميز&nbsp;ببقع حمراء غير مرتفعة أو تشبه الهدف أو دائرية على الجذع ، وغالبا ما تكون مع بثور مركزية وتقشير الجلد وتقرحات الفم والحلق والأنف والأعضاء التناسلية والعينين.يمكن أن يسبق هذه الطفح الجلدي الخطير حمى وأعراض تشبه أعراض الأنفلونزا (متلازمة ستيفنز جونسون ، انحلال البشرة السام).</p><p>&bull; اليرقان (اصفرار الجلد والعينين)</p><p>&bull; الشلل الرعاش ، أي أعراض تشبه مرض باركنسون ، مثل الرعاش ، بطء الحركة (انخفاض القدرة على الحركة) ، والصلابة (تصلب العضلات).</p><p><strong>نادر جدا: قد يصل إلى 1 من كل 10000 شخص </strong></p><p>&bull; قصور الكبد.</p><p>&bull; التهاب الكبد.</p><p><strong>اذا كنت تعاني من تورم الوجهأو اللسان أو إذا تحول جلدك إلى اللون الأحمر وبدأ في البثور أو التقشير ، فيجب عليك طلب المشورة الطبية الفورية</strong>.</p><p>قد تزداد احتمالية ظهور بعض الأعراض الجانبية مثل النعاس في حالة المرضى الذين يعانون من إصابات في النخاع الشوكي بسبب تناولهم أدوية أخرى مثل مضادات الألم والتشنج، والتي تكون تأثيراته الجانبية مثل تأثيرات بريجابالين، لذلك تزداد حدة هذه الأعراض عند تناول بريجاديكس مع هذه الأدوية بشكل متزامن. تم الإبلاغ عن الآثار الجانبية التالية في تجربة ما بعد التسويق: صعوبة في التنفس ، والتنفس الضحل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيدا عن متناول ونظر الأطفال.</p><p>&bull; يحفظ فى درجة حرارة أقل من 30 درجة مئویة.</p><p>&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الكرتون وملصق العبوة بعد انتهاء الصلاحية. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&bull; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. وستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>المادة الفعالة</strong>:&nbsp;بريجابالين. كل كبسولة صلبة تحتوي على&nbsp;75&nbsp;ملجم،&nbsp;150&nbsp;ملجم،&nbsp;300&nbsp;ملجم بريجابالين.&nbsp;</p><p><strong>المكونات الأخرى</strong>:&nbsp;لاكتوز، نشا، تالك نقي، جيلاتين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كبسولة بريجاديكس&nbsp;75&nbsp;ملجم هى مقاس رقم&nbsp;3&nbsp;، كبسولة جيلاتينية صلبة لها غطاء معتم لونه أصفر إلى أصفر فاتح و الجسم يحتوي على مسحوق أبيض إلى مائل للبياض. الكبسولة مطبوعة بـ &quot;PREGADEX 75mg&quot; على كلا الجزأين.&nbsp;</p><p>كبسولة بريجاديكس&nbsp;150&nbsp;ملجم هى مقاس رقم&nbsp;2&nbsp;، كبسولة جيلاتينية صلبة لها غطاء معتم لونه برتقالي و الجسم يحتوي على مسحوق أبيض إلى مائل للبياض. الكبسولة مطبوعة بـ &quot;PREGADEX 150mg&quot; على كلا الجزأين.&nbsp;</p><p>كبسولة بريجاديكس&nbsp;75&nbsp;ملجم هى مقاس رقم &quot;0el&quot;، كبسولة جيلاتينية صلبة لها غطاء معتم لونه بني فاتح و الجسم يحتوي على مسحوق أبيض إلى مائل للبياض. الكبسولة مطبوعة بـ &quot;PREGADEX 300mg&quot; على كلا الجزأين.&nbsp;</p><p>&nbsp;</p><p>تحتوي كل عبوة على&nbsp;30&nbsp;كبسولة&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائية&nbsp;</p><p>مصنع الأدوية بالقصيم&nbsp;</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ نوفمبر 2022                                              النسخة: 1 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pregadex .

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains 75, 150 and 300 mg of pregabalin. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.
Pregadex 75 mg capsule is size no. 3, hard gelatin capsule with opaque light yellow to 
yellow cap and body containing a white to off white powder. The capsule is printed 
with “PREGADEX 75mg” on the both parts.
Pregadex 150 mg capsule is size no. 2, hard gelatin capsule with opaque orange cap 
and body containing a white to off white powder. The capsule is printed with 
“PREGADEX 150mg” on the both parts.
Pregadex 300 mg capsule is size no. "0el" hard gelatin capsule with opaque light 
brown cap and body containing a white to off white powder. The capsule is printed 
with “PREGADEX 300mg” on the both parts
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Neuropathic pain: </u></p><p><strong>Pregadex </strong>is indicated for the treatment of peripheral and central neuropathic pain in adults.</p><p><u>Epilepsy; </u></p><p><strong>Pregadex </strong>is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.</p><p><u>Generalized Anxiety Disorder: </u></p><p><strong>Pregadex </strong>is indicated for the treatment of Generalized Anxiety Disorder (GAD) in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dose range is 150 to 600 mg per day given in either two or three divided doses.</p><p><u>Neuropathic pain</u></p><p>Pregabalin treatment can be started at a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.</p><p><br /><u>Epilepsy</u></p><p>Pregabalin treatment can be started with a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week.</p><p><u>Generalized Anxiety Disorder</u></p><p>The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly. Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an additional week the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional week.</p><p><u>Discontinuation of pregabalin</u></p><p>In accordance with current clinical practice, if pregabalin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections 4.4 and 4.8).</p><p><u><strong>Special populations</strong></u></p><p><strong>Pediatric Use: </strong></p><p>The safety and efficacy of Pregabalin in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p><strong>Geriatric Use (over 65 years of age):</strong></p><p>Elderly patients may require a dose reduction of pregabalin due to a decreased renal function (see patients with renal impairment).</p><p><strong>Patient with renal impairment: </strong></p><p>Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. As pregabalin clearance is directly proportional to creatinine clearance (see section 5.2), dose reduction in patients with compromised renal function must be individualized according to creatinine clearance (CLcr), as indicated in Table 1 determined using the following formula:</p><p><br /><img alt="" width="572" height="79" src="data:image/png;base64,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" /></p><p>Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4-hour haemodialysis treatment (see Table 1). Table 1. Pregabalin dose adjustment based on renal function:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance</p><p>(CLcr )</p><p>(mL/min)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Total pregabalin daily dose * Dose regimen</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dose regimen</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Starting dose (mg/day)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maximum dose (mg/day)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge;60</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>BID or TID</p></td></tr><tr><td style="vertical-align:top"><p>&ge;30 - &lt;60</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>BID or TID</p></td></tr><tr><td style="vertical-align:top"><p>&ge;15 - &lt;30</p></td><td style="vertical-align:top"><p>25 &ndash; 50</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>Once Daily or BID</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 15</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>Once Daily</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Supplementary dosage following haemodialysis (mg)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>Single dose+</p></td></tr></tbody></table><p>TID = Three divided doses</p><p>BID = Two divided doses</p><p>* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose</p><p>+ Supplementary dose is a single additional dose.</p><p><strong>Use in patients with hepatic impairment</strong></p><p>No dose adjustment is required for patients with hepatic impairment (see section 5.2).</p><p><strong>Method of administration</strong></p><p>Pregabalin may be taken with or without food.</p><p>PREGADEX is for oral use only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Diabetic patients</u></p><p>In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycemic medicinal products.</p><p><u>Hypersensitivity reactions </u></p><p>There have been reports in the post marketing experience of hypersensitivity reactions, including cases of angioedema. Pregabalin should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur.</p><p><u>Dizziness, somnolence, loss of consciousness, confusion, and mental impairment</u></p><p>Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. There have also been post-marketing reports of loss of consciousness, confusion and mental impairment. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicinal product.</p><p><u>Vision-related effects</u></p><p>In controlled trials, a higher proportion of patients treated with pregabalin reported blurred vision than did patients treated with placebo which resolved in a majority of cases with continued dosing. In the clinical studies where ophthalmologic testing was conducted, the incidence of visual acuity reduction and visual field changes was greater in pregabalintreated patients than in placebo-treated patients; the incidence of fundoscopic changes was greater in placebo-treated patients (see section 5.1). In the post-marketing experience, visual adverse reactions have also been reported, including loss of vision, visual blurring or other changes of visual acuity, many of which were transient. Discontinuation of pregabalin may result in resolution or improvement of these visual symptoms.</p><p><u>Renal failure</u></p><p>Cases of renal failure have been reported and in some cases discontinuation of pregabalin did show reversibility of this adverse reaction.</p><p><u>Withdrawal of concomitant antiepileptic medicinal products</u></p><p>There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.</p><p><u>Withdrawal symptoms</u></p><p>After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed in some patients. The following events have been mentioned: insomnia, headache, nausea, anxiety, diarrhea, flu syndrome, nervousness, depression, pain, convulsion, hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment. Convulsions, including status epilepticus and grand mal convulsions, may occur during pregabalin use or shortly after discontinuing pregabalin. Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity ofwithdrawal symptoms may be dose-related.</p><p><u>Congestive heart failure</u></p><p>There have been post-marketing reports of congestive heart failure in some patients receiving pregabalin. These reactions are mostly seen in elderly cardiovascular compromised patients during pregabalin treatment for a neuropathic indication. Pregabalin should be used with caution in these patients. Discontinuation of pregabalin may resolve the reaction.</p><p><u>Treatment of central neuropathic pain due to spinal cord injury</u></p><p>In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased. This may be attributed to an additive effect due to concomitant medicinal products (e.g. anti-spasticity agents) needed for this condition. This should be considered when prescribing pregabalin in this condition.</p><p><u>Suicidal ideation and behavior</u></p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomised placebocontrolled studies of anti-epileptic drugs has also showna small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known. Cases of suicidal ideation and behaviour have been observed in patients treated with pregabalin in the postmarketingexperience (see section 4.8). An epidemiological study using a self-controlled study design (comparing treatment periods with nontreatment periods within an individual) showed evidence of an increased risk of newonset of suicidal behaviour and death by suicide in patients treated with pregabalin.</p><p>Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. Patients should be monitored for signs of suicidal ideation and behaviour andappropriate treatment should be considered. Discontinuation of pregabalin treatment should be considered in case of suicidal ideation and behaviour.</p><p><u>Reduced lower gastrointestinal tract function</u></p><p>There are post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, constipation) when pregabalin was coadministered with medications that have the potential to produce constipation, such as opioid analgesics. When pregabalin and opioids will be used in combination, measures to prevent constipation may be considered (especially in female patients and elderly).</p><p><u>Misuse, abuse potential or dependence </u></p><p>Cases of abuse have been reported. Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin abuse.</p><p>Cases of misuse, abuse and dependence have been reported. Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin misuse, abuse or dependence (development of tolerance, dose escalation, drug-seeking behaviour have been reported).</p><p><u>Encephalopathy</u></p><p>Cases of encephalopathy have been reported, mostly in patients with underlying conditions that may precipitate encephalopathy.</p><p>Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported rarely in association with pregabalin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, pregabalin should be withdrawn immediately and an alternative treatment considered (as appropriate).</p><p>&nbsp;</p><p><u>Lactose intolerance</u></p><p>Pregadex contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><u>Concomitant use with opioids</u></p><p>Caution is advised when prescribing pregabalin concomitantly with opioids due to risk of CNS depression (see section 4.5). In a case-control study of opioid users, those patients who took pregabalin concomitantlywith an opioid had an increased risk for opioid-related death compared to opioid use alone (adjusted odds ratio [aOR], 1.68 [95% CI, 1.19 &ndash; 2.36]). This increased risk was observed at low doses of pregabalin (&le; 300mg, aOR 1.52 [95% CI, 1.04 &ndash; 2.22]) and there was a trend for a greater risk at high doses of pregabalin (&gt; 300 mg, aOR 2.51 [95% CI 1.24 &ndash; 5.06]).</p><p>&nbsp;</p><p><u>Respiratory Depression</u></p><p>Pregabalin has been associated with serious, life-threatening, and fatal respiratory depression. The risk may be increased with the concomitant use of opioids and other central nervous system (CNS) depressants, and with conditions such as chronic obstructive pulmonary disease. The elderly is also at higher risk. Health care providers should start pregabalin at the lowest dose and monitor patients for symptoms of respiratory depression and sedation when co-prescribing pregabalin with an opioid or other CNS depressants (eg, benzodiazepines). Patients with underlying respiratory disease and elderly patients are also at increased risk and should be managed similarly.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (&lt;2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.</p><p><u>In vivo studies and population pharmacokinetic analysis</u></p><p>Accordingly, in vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance.</p><p>&nbsp;</p><p><u>Oral contraceptives, norethisterone and/or ethinyl oestradiol </u></p><p>Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance.</p><p>&nbsp;</p><p><u>Ethanol, lorazepam, oxycodone </u></p><p>Pregabalin may potentiate the effects of ethanol and lorazepam. In controlled clinical trials, multiple oral doses of pregabalin co-administered with oxycodone, lorazepam, or ethanol did not result in clinically important effects on respiration. In the post marketing experience, there are reports of respiratory failure and coma in patients taking pregabalin and other CNS depressant medicinal products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.</p><p>&nbsp;</p><p><u>Opioids and CNS depressants </u></p><p>Serious respiratory depression may occur with pregabalin when co-administered with opioids and CNS depressants such as benzodiazepine. Therefore, monitor for symptoms of respiratory depression and sedation in patients who require concomitant treatment with opioids or CNS depressants.</p><p><u>Interactions and the elderly </u></p><p>No specific pharmacodynamic interaction studies were conducted in elderly volunteers. Interaction studies have only been performed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential have to use effective contraception during treatment (see section 4.4). Women of childbearing potential/Contraception in males and females As the potential risk for humans is unknown, effective contraception must be used in women of child bearing potential.</p><p><u>Pregnancy</u></p><p>Studies in animals have shown reproductive toxicity (see section 5.3). Risk related to epilepsy and antiepileptic medicinal products in general Pregabalin has been shown to cross the placenta in rats (see section 5.2). Pregabalin may cross the human placenta.</p><p>The risk of birth defects is increased by a factor of 2 &ndash; 3 in the offspring of mothers treated with an antiepileptic medicinal product. Most frequently reported are cleft lip, cardiovascular malformations and neural tube defects. Multiple antiepileptic drug therapy may be associated with a higher risk of congenital malformations than monotherapy, therefore it is important that monotherapy is practised whenever possible. Specialist advice should be given to women who are likely to become pregnant or who are of childbearing potential and the need for antiepileptic treatment should be reviewed when a woman is planning to become pregnant. No sudden discontinuation of antiepileptic therapy should be undertaken as this may lead to breakthrough seizures, which could have serious consequences for both mother and child.</p><p>Major congenital malformations</p><p>Data from a Nordic observational study of more than 2,700 pregnancies exposed to pregabalin in the first trimester showed a higher prevalence of major congenital malformations (MCM) among the paediatricpopulation (live or stillborn) exposed to pregabalin compared to the unexposed population (5.9% vs. 4.1%).</p><p>Risk related to pregabalin</p><p>The risk of MCM among the paediatric population exposed to pregabalin in the first trimester was slightly higher compared to unexposed population (adjusted prevalence ratio and 95% confidence interval: 1.14 (0.96-1.35)) and compared to population exposed to lamotrigine (1.29 (1.01&ndash;1.65)) or to duloxetine (1.39 (1.07&ndash;1.82)).</p><p>There is a limited amount of data from the use of pregabalin in pregnant women. A population-based cohort study of 2,712 pregabalin exposed pregnancies indicates a slightly increased risk of major congenital malformations associated with the use of pregabalin in pregnancy. However, this study was subject to some limitations and further data are needed to reach a definitive conclusion.</p><p>The analyses on specific malformations showed higher risks for malformations of the nervous system, the eye, orofacial clefts, urinary malformations and genital malformations, but numbers were small and estimatesimprecise. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>Pregabalin should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus).</p><p><u>Breast-feeding</u></p><p>Pregabalin is excreted into human milk (see section 5.2). The effect of pregabalin on newborns/infants is unknown. A decision must be made whether to discontinue breastfeeding or to discontinue pregabalin therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman</p><p><u>Fertility</u></p><p>There are no clinical data on the effects of pregabalin on female fertility. In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no effects on sperm motility. A fertility study in female rats has shown adverse reproductive effects. Fertility studies in male rats have shown adverse reproductive and developmental effects. The clinical relevance of these findings is unknown (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="rtl">Pregadex may have minor or moderate influence on the ability to drive and use machines. Pregabalin may cause dizziness and somnolence and therefore may influence the ability to drive or use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pregabalin clinical programme involved over 8900 patients who were exposed to pregabalin, of whom over 5600 were in double-blind placebo controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity.</p><p>In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence. In the table below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>The adverse reactions listed may also be associated with the underlying disease and / or concomitant medicinal products. In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased (See 4.4). Additional reactions reported from post-marketing experience are included as Frequency not known in italics in the list below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Drug reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Nasophryngitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutropenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity,</p><p>Angioedema, allergic reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Appetite increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anorexia, hypoglycemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Euphoric mood, confusion, irritability, disorientation, insomnia, libido decreased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hallucination, panic attack, restlessness, agitation, depression, depressed mood, elevated mood, aggression, mood swings, depersonalisation, word finding difficulty, abnormal dreams, libido increased, anorgasmia, apathy</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Disinhibition, suicidal behaviour, suicidal ideation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Dizziness, somnolence,&nbsp;headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Ataxia, coordination abnormal, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, stupor, myoclonus, loss of consciousness, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, cognitive disorder, mental impairment, speech disorder, hyporeflexia, hyperaesthesia, burning sensation, ageusia, malaise</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Convulsion, parosmia, hypokinesia , dysgraphia, parkinsonism</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vision blurred, diplopia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, dry eye, lacrimation increased, eye irritation</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vision loss, keratitis, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperacusis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tachycardia, atrioventricular block first degree, sinus bradycardia, congestive heart failure</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>QT prolongation, sinus tachycardia, sinus arrhythmia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypotension, hypertension, hot flushes, flushing, peripheral coldness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pulmonary oedema, throat tightness</p></td></tr><tr><td style="vertical-align:top"><p>Not Known</p></td><td style="vertical-align:top"><p>Respiratory depression</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting, nausea, constipation, diarrhoea, flatulence, abdominal distension, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastrooesophageal reflux disease, salivary hypersecretion, hypoaesthesia oral</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Ascites, pancreatitis, Swollen tongue, dysphagia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong>&nbsp;&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:1386px"><tbody><tr><td style="vertical-align:top; width:108px">&nbsp; &nbsp; &nbsp;Uncommon</td><td style="vertical-align:top; width:1275px"><p>Elevated liver enzymes*</p></td></tr><tr><td style="vertical-align:top; width:108px"><p>&nbsp; &nbsp;Rare</p></td><td style="vertical-align:top; width:1275px"><p>Jaundice</p></td></tr><tr><td style="vertical-align:top; width:108px"><p>Very&nbsp;rare</p></td><td style="vertical-align:top; width:1275px"><p>Hepatic failure, hepatitis</p></td></tr></tbody></table></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash papular, urticaria, hyperhidrosis, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Stevens Johnson syndrome, Toxic Epidermal Necrolysis, cold sweat</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp; &nbsp;&nbsp;Common</td><td style="vertical-align:top">&nbsp; &nbsp; &nbsp;Muscle cramp, arthralgia, back pain, pain in limb, cervical spasm</td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urinary incontinence, dysuria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Renal failure, oliguria, urinary retention</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Sexual dysfunction, ejaculation delayed, dysmenorrhoea, breast pain</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Amenorrhoea, breast discharge, breast enlargement, gynaecomastia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oedema peripheral, oedema, gait abnormal, fall, feeling drunk, feeling abnormal, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Generalised oedema, face oedema, chest tightness, pain, pyrexia, thirst, chills, asthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased, blood glucose increased, platelet count decreased, blood creatinine increased, blood potassium decreased, weight decreased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>White blood cell count decreased</p></td></tr></tbody></table><p>After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed in some patients. The following reactions have been mentioned: insomnia, headache, nausea, anxiety, diarrhea, flu syndrome, convulsions, nervousness, depression, pain, hyperhidrosis and dizziness. The patient should be informed about this at the start of the treatment.</p><p>Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.</p><p>Paediatric population</p><p>The pregabalin safety profile observed in five paediatric studies in patients with partial seizures with or without secondary generalization (12-week efficacy and safety study in patients 4 to 16 years of age , n=295; 14-day efficacy and safety study in patients 1month to younger than 4years of age, n=175; pharmacokinetic and tolerability study, n=65; and two 1 year open label follow on safety studies, n=54 and n=431) was similar tothat observed in the adult studies of patients with epilepsy. The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis. The most common adverse events observed in the 14- day study with pregabalin treatment were somnolence, upper respiratory tract infection, and pyrexia (see sections 4.2, 5.1 and 5.2).</p><p>&nbsp;</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:629px"><tbody><tr><td colspan="2" style="text-align:center; width:626px">&nbsp; &nbsp; &nbsp;&nbsp;PV address&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</td></tr><tr><td style="text-align:center; width:238px">&nbsp; English</td><td style="text-align:center; width:411px">&nbsp;Arabic</td></tr><tr><td style="width:238px"><p>For Saudi Arabia:</p><ul><li>&nbsp;The National Pharmacovigilance and Drug Safety Centre (NPC)</li><li>Reporting hotline: 19999.</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul></td><td style="width:411px"><p dir="rtl" style="text-align:right">المملكة العربية السعودية&nbsp;</p><ul><li dir="rtl" style="text-align:right">المركز الوطني للتيقظ والسلامة الدوائية:</li><li dir="rtl" style="text-align:right">&nbsp;مركز اتصال هيئة الغذاء والدواء&nbsp;:&nbsp; 19999</li><li dir="rtl" style="text-align:right">البريد الإلكتروني ; npc.drug@sfda.gov.sa</li><li dir="rtl" style="text-align:right">&nbsp; الموقع الإلكتروني : https://ade.sfda.gov.sa</li></ul></td></tr><tr><td style="width:238px"><p>For UAE</p><ul><li>Pharmacovigilance &amp; Medical Device section</li><li>P.O.Box: 1853 </li><li>&nbsp;Tel: 80011111</li><li>&nbsp;Email: pv@moh.gov.ae</li><li>Drug Department Ministry of Health &amp; Prevention Dubai</li></ul></td><td dir="rtl" style="width:411px"><p style="text-align:right">الإمارات العربية المتحدة</p><ul><li style="text-align: right;" dir="rtl">&nbsp;قسم اليقظة الدوائية والأجهزة الطبية</li><li style="text-align: right;" dir="rtl">&nbsp;صندوق البريد: 1853</li><li style="text-align: right;" dir="rtl">هاتف: 80011111</li><li style="text-align: right;" dir="rtl">&nbsp;البريد الالكتروني pv@moh.gov.ae</li><li style="text-align: right;" dir="rtl">&nbsp;قسم الأدوية، وزارة الصحة والوقاية، دبي.</li></ul></td></tr><tr><td style="width:238px"><p>For Oman</p><ul><li>&nbsp;Department of Pharmacovigilance &amp; Drug Information</li><li>&nbsp;Directorate General of Pharmaceutical Affairs &amp; Drug Control</li><li>Ministry of Health, Sultanate of Oman</li><li>Phone Nos. 22357687 / 22357686</li><li>Fax: 22358489</li><li>&nbsp;Email: dg-padc@moh.gov.om</li><li>&nbsp;Website: www.moh.gov.om</li></ul></td><td dir="rtl" style="text-align:right; width:411px"><p>&nbsp; &nbsp; &nbsp; سلطنة عمان</p><ul><li dir="rtl">&nbsp;دائرة التيقظ والمعلومات الدوائية</li><li dir="rtl">&nbsp;المديرية العامة للصيدلة والرقابة الدوائية</li><li dir="rtl">&nbsp;وزارة الصحة، سلطنة عمان</li><li dir="rtl">&nbsp;هاتف: /0096822357686 0096822357687</li><li dir="rtl">&nbsp;فاكس : 00968522358489</li><li dir="rtl">البريد الالكتروني: dg-padc@moh.gov.om&nbsp;</li><li dir="rtl">الموقع الالكتروني :&nbsp; www.moh.gov.om</li></ul></td></tr><tr><td style="width:238px"><p>For Jordan</p><ul><li>JFDA&rsquo;s site: Jfda.com</li><li>JFDA PV email: jpc@jfda.jo</li><li>&nbsp;JFDA reporting link: https://primaryreporting.who.umc .org/JO</li><li>Phone: +962-6-5632000</li><li>QR code</li></ul><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFgAAABRCAYAAABWmmH8AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAABmdSURBVHhe7Zx3zFVF0MaPBbuIKCAq9o6Kgr2gIGLBAiJgARVNVKwRBUs0sVPsRiwIGo2IHTUROyoKRmygYhd7QRSxd+83v+E+hznnvZUXvu+PjyeZ7Dmzu7PlzO7MlnsXSwIKhuLjIiwgLF4MF2EhYVEHL2RU7ODFFlus0dS/f//kv//+Y/ppQL/++muy+eabe7oBAwZ4uohRo0Y1kFcvLb300smzzz7rsmM9dt5555Lp66VqqEmDaxEkkHaJJZYovs0DjVIDhXyHNhalygXq1HLlLbnkkjW3sdaOFZYshhXB195jjz2qCqYRpPnnn3+S6667LpkzZ04xZm7csGHDkj///LPISZJ///03+fbbb4tv9YFyBg4cmKywwgpFTuLl3nzzzS6zXbt2yQEHHOCdPnHiRKdNNtkk6d27dzH1XKyzzjrJ0UcfnX78Sm3Uh7r//vuT6dOnF7l1wDJnAAs688wzC1aBimSdlYa///57Ye211/a8Rx11VBq37LLLpjLzdPzxx3u6COuskmkh64jCzJkz0zKh3377rWCd6PF9+vQp/P3334U//vij0KlTJ+cdfPDBaX132mkn5+2+++5pfsWVI9LYRywceOCBaT2qoS4jZwUkn376aTJjxozkk08+aUDfffedf+E80IqoGSuuuGKy7rrruvZA9jGSVVddNdUQQBjTMZfmIZnWscnHH3/sdaOOIJaJ7PXWWy9p1aqVv+ehMr/++uuS7YKIi3WbL1jGDGBB0mAbeoUtttiiYBUurLLKKg3oggsu8C+c12DyAjTYGl3Yb7/9CvYxCrNmzUrpxx9/9LxKS/jLL794HOWaMUzrAyEHPumefvppr1OLFi0KNp96/CGHHOLy0LoffvjBy7MpK9XUUhrcrVu3ku2C0FratVA1GKCl0Pfff9+ArEOKqUpDGrXUUkslzZs3T1ZeeWUnnplLFW/18tA+iMdZA5PFFy9fVbRWdeA5AplNmzb1chgReagsgM2I7Yn0888/p2ljnmqou4PrES6Qx7QmGT58eHLllVcm7du3T0477bTkrLPOSo2cOpd0N9xwg8djxERffvmlx0cgF9pwww2Tq666yo1oy5Yti7HzgOxIpQC/WtuUt5yMqrACMoAFxSmidevWKT9PgwYNKjtFaBhCZoU9brnlliu89dZbmTioS5cuGbmlyBrp9SG95GPkNt10U4/XFJEHaaE4RYhn3lKmjEjmRbnBpJyFOkXMD6wcJ7Tws88+8ylGsDnW+TZPNtAgpog11lgjWXPNNUsauc8//9zzMgqUNy/j/xp1dbA6an7AsDKtSTp06OBDHpimJ6YNyZZbbplceumlzoswtyqZNm1aMnXq1GT99dcvcueCenTu3NnznnDCCUVudviqvpHyqBYv1Jouj5o6OFZ6fuYf8kCzZ892YokMqOhPP/3kxoXOVjph+eWXdyMHlSoXw0NeZCheYb4TynVOKbkLEjWt5FQpLP3VV1+ddoag+M0226ymCm+33XaudazqLr74Yh/q9QKv4tprr3XPgCmCPQ+bc5NvvvnG46dMmeI8oDoxek466aSSdbQ5ODnnnHPcY4hQ21ZbbbWyS/GaYcIygAUNHjw4NUDyLWUYIimulJGDMGrwunfv7unwffGr4WklRzoZOXjK27ZtW+eJ8HetMz3PE088UbDGF6zTnYi3Tsyk571Xr15pGTJyu+22m/MqtQsiDmJ1aEvwVG41VJ0i+Nr4txiTr776ylc0hLznSXGQVaYoYR6sPA+RCaGFVnnnCUoj8C4C9pGS1Vdf3QnNpSymiLXWWsu1TP5yTLfMMss4D1BuLIN6MoJU71LtypN5E8XcdcIKzgBWY6mUBvfo0cPfWanZtOI8tFVaJA0+7rjjUs1RusMOOyzVKFZv1mGFrl27et5SbhqjCS2Fp70I8kqDG0vVsNDdtCZNmhSfvDbFp3lAo4A13ENrfJoOnp5Z/UnrxZM2QpKjUGlAjIt8QfELAxWN3C233JKpfP5ZKFVB4umMjTfeuMhp2Pgo45lnnnGjRJp99903Ofzww32FpjwXXXSR+8ps/gjK//bbbyc2UjwtQxiUqxN8Pty5557rU5rSSRbvsV6C8kbMnDmz+FQjTEhZaGgRiuK7EONEetd2pYyczZ3p0I+E0crL0bNChj9TRD6vSFMEqy9Wa/DiFCGKEC9fVj7U8/vvv1/MWR4VNfj5558vPlnt7Auy87/11lv7quqLL77wLUJcl6222spdONIAq0Dy6quvNthc33HHHd2V4pgIoBHbbLONbyeiTR988IHz3njjDS+D7UW0GLz++utubNlr2GijjTxdx44dfSUowKNc+dnlQD0pAz86aqV1mocrrbRSYt6NP9tSPnNwANi4b9GiRfGtDtDjEbg8IqtIwRpXsCHomjFs2DDno0XTp0/3LyrCsNhQTvNBuFFoLHlxddACQt6hG2+8MVMW1ZGRI759+/bumvXr1y/l/fXXX2l+yDo2HRGVNBg++w6UozIjYRRVN5uunKe0tOPBBx+sWYMrGjkTkmolIVpohaRfnXgRIB5SPoi0hEoDkAEkRzIlS2UCpZG8CMkRn7SMqJgnhvD1rHJULz2LlJZQ8mIetbMa5uYswjJnWnDrrbd6+NhjjyX33HOP78tyFsUwZei88sor7m/uueeevt/6yCOPJPfdd59XiNUa/ucLL7zgxpLO6NOnj3sDAs/nnXeeb+hwgmwaW4yZC96vv/56b9T48eNTI8cZITj11FN9mDNkBw0a5OmoA8txTjB22WWXxDQx2XvvvZPnnnvOT0ZMO71jaBPTC3nPPvts7zCADKYY2kY7mCpoN3wIHn3AhhX+9wMPPOD5aoIJyMAKdRo6dCgd79MBqyeroJPi9TxkyBBPZ/NnYcaMGc4bPXp0OuTzhF/85ptvev6bbrqpQXz0g2N5Ihk5+8AN4kSaIsrVgTimAtISUs7EiRPT+IcfftjjVP4CX8lZGl8NoQ3bb7+9+7XwAF9T4LlNmzaeDmPGV37xxReTjz76KE0voBFoIekYAcTn04AoH+g9z7cldzJp0iQvT/skaOfkyZOdh6YBRh71E1EH6kwa5SfEAGraeuedd1yO4iGML3nZ26gL1sgMpAV8Wb6cSPw8EWeeg6/QbIi6QYAQHYkNawwUpLwYuXw67U+IItAoabB1hhtARgQb+MTdfffdBVMGL986ytP17NnT2xKJ8zzSkB/Ss/IgW+2AbFor2DTobTX/u1ib8qiqwXxFiC9qBaRGBIpQGquch9YhKeWBDKWTnLw8YB1VfJoLq28aQspDOsqBx7NCkfKpjnkir3W2k56VR7JFxFF/8hFWQ8UOZhgwlEy7/J1CRWPGjPEN9G7duvmxNry77rrLjQi8ESNG+NAaPHiw5xVoJJdAmB40nSDnsssua9DJ5g55HfB38bnVaEBavZMfn9200Q0Z6NSpk/O4NoXvHkFeUSmQnjoyLSA7gjIr5a0Iy5wBLIgzOft6PvQgnocPH+5xzZs3T8/V5Bub9+BGjiE4cuTIsgamFJE/vpMXni00XF6sg9kGT2Negk83mr4UD2HkuHiCHC6jKF7EFBHLg+zDp1PIPvvsk9ZfdTHPweW8++67xZ4qj4oabAI9xD1ilWWOdUpaQVkl/cIHPMDKi/0HVnrkYTUHj9WXQtEGG2yQ2UoEyMNti3mQx0Z6rMN7772X1g/D9uGHH/qFGK0eGcKQtdG3MjkMYHNe+SWDLU9ctVi/1q1bJ9Z5Xh7uJ+VrZAC2NclPu+vC3D6fB1j1UKlT5SOPPNI1BSgUzIetuBchLYRKpcsTIwe3L0JyqJf58g3yyE2L5ZnP7NoKPfTQQ8576qmn3P3M56+GqhqcpzzQEkHxJtdDILcuUkQp2fFZeShH/JhHJPAcy4LEt05Mn5UnpolQGqUTyvHLIZPKCsqUxBDJgyQI5xYjhomNkdtvv92HGas4c4/8uJ0LJmzisLKyRYR7DS+99JLHqXKmGW4gafjYsWOTCy+80J+ffPJJv81p2uPnZIBLK0wpWG5VEzk8s9XJ/WLeWenFj6H6IpdT6NNPP935AlMUU5LSA1aHTHEoB6ckbGSx0cSGVFQoDG/Xrl2LbzXAKlMVDCVIRq5Zs2ap75lfyTH0WMnBswb4ZgzpBMliCLKSIw1prYM9Pt6uZOhrCOeJKUV5K1HcrlSYJ9UpHx/z6dnmcK9nJVTcrkSDIix9+qV1P5Z3iDiBZ7SQlRPGsHv37s5/9NFHXZMjlI/VU5QB9I7WTJgwwY0YBogtTuLYT8CoYXRUBohyrDN85GDMBOJxwzDejDJcMdqAWxcvwKhdMYygXIxizTAhGZhAd0tE8Z3kkFlZ367ki6LBpFE6wmOPPdbj0Gaz4iVliiRTGhxdPKXv27dvqkGsFonfa6+93EWTdolIU+5MDleMvDJy0K677pqpU/45vouqoaKRs3jXAOYiLoEwFxFCuDwQPNwk5i3zRT2fFex7DMSRl3erXLpCQqaId1EE7+RDhsqhXDbilZYyeaZc5kj2HOBB3BlGPkAO4J040pGHvNbZ/k5++0iZOvGMzaBc5mrxeaY+tLEaMjpvmTOtVMX69++fnHzyyek7UFIaMnToUDcKOkZnG3LcuHE+nLmVgx8KqCgfoxpk5LgEgtxYLfxSLmzDYwoiDR8A4xbrZwsEP8fjo2q7krzUhbxsQrEtSZ0wngBfOn8awkUbVpIvv/yyX1rhg1xxxRW+YsUPjlNTVVjBGcCC4kpOoWj27NkNfFQ2RDBySkMeiM2YmK4clfKDJSvytdlTijjRYNqIU0S9ZB/M/WDKlB/MNKETjVqMXE0ajCtic5VryhFHHOHDgzgIo8CeAie72267rbtC1ni/9KyNIYllWzEaOQzUbbfd5pvXXOJD09A4hh5DUyAPp8Zsc7L6Yo9CZTMFwWPjm/JsYeOa3bZtW//Bi3VEYnO0a7BA3kMPPTSzOisHTrdZybGnwWk39aMsfmCDxrP6qxl0cAQsiK9GyBV9mwJSjQJRg7liZRVwd0wrOWtMKgM+eQH5be5L87K5jsaxp5C/H4yMadOmed4777wz5elHMHLT0DDzRpxHWiieyUWaNGlSph2EpUhy0GBGZtRgWy573kqoaOQAXxsCJjTjxOdh8opP80B6oDjljXKB3sttASotdQC8o02SSwjBVwiRXmkE1UkylVfpyKNyxFNaUEpmOVTsYHbzobj6qUUww9a+uOe95JJLMpUDsTExLjY4Av7+++/vQ5VVG3KZkpgylIcwPqsMDC7TEHnYwFFeDDPyWIEScpWAqwGAo38bWR7H1IAcpj98dc4iMeDEcRZZDRU7mIKxsFhfIO3Nd0AepOPQkfkJR14NJ5+0QzKiLBuKqeYIKo8Lesx5eC3UCwefD6k0lJmvH88QN+SpC5e41SZcM+SxHSDSThwuHF4GPMpDHnaBfMjhngRxteymVVzJ6dY5jebkFR80Gp9yID37D7qwQV4qLQPHVp9OY3v27OmuDp11+eWXe2PYnwBcaMHdgscJd7yqpM4jDtfrjDPOcD6/wqSjMXIYIurC/gjuHlrHjXryccLNZr4+BuDskXf2JjgoIB2KQkhncrLOtMQexHzBhGcAC9KPYGQUIpkfmhqqcj+CkaFQfjasicNt06lypTM54nU/2Kx/WnaeKFe3K+MvPWXktJKDYlti3SJFnoyc6iaqhopTBFrFqoXQ0joxjNBGiGdrgBsm5roYLx5ar/SSAYiDrBGeB62jLHhojBCfAe+Qyor1oS7kp76qs3WO14V6EKc6sGpTPhF1kXxIU46o0bCCM+C+La4VWsDXtJVaweYh39i2qcKJn3VNnTrV03JkZCsjP0bCCSfviBEjXFPh45ah4dYYj5s1a1ahXbt2Lo89C+Ih/ba41A137gcD5Ng87HlVH9zIKVOmeF3QZtJQb7WDEFnw0WryKD/1w3UrB46W7AOlmiuqhooabAX7nCutsvS+ZkdTWPJCPKMtaAgaYI3wNPDIiwx4EJqEHELiyIMmoYXwWLZCPFcD2sUNHspXfdhnwBhJW6V51AGCD+Chsao/RP3Q9gWNikaODXXA9iCntFSeH6+wImNtzpZfBBdTcOloAIaFjuLHKICPowYLfARWaBivHXbYwRtIuoMOOsj/jgDXiHeI/RDO5Tjx5R1IFkauV69eLg+PJ5bBR8c46d4wID+b53nccccdfrEEY2dLbZeD0cTo8kFOOeUUT0d+4lhJ1gXLmAEsSHsREIYDYjogjulA25UMPYjhiJGzSmQIvuRoqCJL+Xhm+uBZ8qJckfJrL4KrU/k4wbQzPVWG1Kb4nCe2LSWPU2V4yGCKQb6o0afKuCj4fuyICRrmHBURz3oe9wseBAjRKna4SCOfGPcG/1LullXS3Sc0hDhcIX4JypSBDKYBwDMaSBqdZucRy8/D2ukheyiqjwjfWCHTliBZqgN1op5s+ovq/vnZ3D6fB4wQhOFBKyKhjRg94tE6eNIeQtw3xUM8t2nTxrVOJ802V/s9XXiili1b+qmuZElex44dPT4aPt6pNhoc0xIKaLDcNC7tqU6EebIpLtVgyeKvF+Bh4GI9IQ4bqqGiBpsQJ3bRpCEi5mNueRPP3AcvujXNmjXzOLSfJS3P7N3q2iew8n0egyeyhvp8h4wI5WX+Jx9QSFqe9V4OGD7ViZB6iXiPO30q3zraQ+oU6wnVMgdXNHKswOYHsQO4J9yjRw/vfPE5z0M2HgQdCjgXY+UFmJYEdRzGk05mNZbvfJat/DUCHcSmOBv9lYA87h0zPTE9HHPMMcWYLEjH9ieb60xP3GGmw/v165fYgsY7uS6YwAxgNZas8j7UAH5nqTSQeScZI5Un+CLxTPMyMvBntTIU4hQRz+TsgzqPOJUrHlMEUFpC+cGmKIVx48Y5v5YN94pTBEBb8E25H8C9WMJSFON4li9rFfHQynLNIq6UHKYcysprJyAv2oKbhoGE4k+wGPrIZMpi2JKO0DrG48kfwTvTAnlkwGMaRhZHX5TDCEOe2Zy07vjPxC0wDR44cKD/702kOXPmZCjGWYXcoJHX/Ff/2rhgbM7HdCLyY/DQpKg1hCK0yzwXP5lu2rSpk3WwU+fOnf0/eSi3Q4cOnoY9EMq0zshoMLIoB8NN2YS8Qxhc0plyuAwRZXFyjSGkDfzmGR6rv2qoqsGAuY0jICssJZ32xmdCCBdOGmxleMgcDJ90yCIdoeTiIqGRpEfzRAJuEsaRFZdOjkkLRdla0REKpEE2dVIeRgzpCYHKBoRafUJoL3VR+9Bw6gK/GioaOYHCIZbAbKCbxvm7oAZ06dIlPWVVZQFx8Z0/2Bg5cqQPbYwTUwQgHQ3hbwo4Z+OsjzMxwBUqc698ZciPaiLY/tSfcmiFhizVUeWzoR7/vAMoDtI2JEZW25+qE94LfyTCMxvvylcXLEMGsKD4nz3WGSk/T5X+swfScM9vV4qv4Rt/DK68yj9mzJi0vEoUT5U1RdRK8oMhQFjqdqV1ssdXQk1TRGNgZfhXJ2Q1hobhbgloAmAoEodxYfMFKE4hYCrBWFYjNneQBzGs2V+Ar1AbP4SMIOUBMnKqD6HN1x4HMJCkx3euC97lAbCgxmowmoc2WUPdgODqEMe7NJhrUvCJlzyt2gChjBHpxS8F4seOHes/ZkHrJkyY4DzlQ4YMGncmqBs8NBcemqk66h3imfrJTVsgp8oLChgYq5STNdJ5hGgnZHXxd+LzII40GDOIZ/EVRgKkiWUBxSFDkFxCpSVdPp/yAtJCkVcONRm5CATPD6gw/8jK8OOfpPjzOZ7PP/9832LksgjneIDrSpz+AhqhxsSy1ThCTomvueYa93b4mwIZzTxee+01v9cM2BLt27dveg4HFJYCh6WsEimDH8dw7xlPgh/+1AwrIANYUJwibO5J+Xmqdian4a0/pos0YMAAj4f4Ezh4nHJQrigi8h9//HFPz0pLKzlruA/rJk2a+CoMufcUf0IAn9ML0qlMSNNGKdJ2JdOJeUopvxrq0mC+HhvhnLqCvEZxPF4JuDdoLXsHgGmDvQV8UeVFpuRiXLijAJCfL493Qo7f9Yw24wOznShQHv623LAoCy0kPzy2WNnUEeAJaDruJXXGuHEYIGNcM0xgBrAgaTBf2Zx4J1ZeIt5ZEaG5aGg5DWYrktUPewbE4aZxhhbzQnLTMFKkJx1h/lkU9zh4hqcyIJ4xqJE3efJkL4utUdITj6arfbGdhOPHj/fb/KS79957ncdZZDXUZOQsXTrp4yahcYQi3iG2LUkLlQILFVY/8cuTzxroiw6VQ4iGWQd4eq2m9CwSD40VkE2cNu0heJRNyDtGTfU0pUnlUf/YJuqlEHcupoNHumqYN+YMVmCmZ1RBrhVxlUi8XDJH5NNJ/P0AjTcNTkaPHu18+/qZzqCSXO9n64+fCOjvEzjbY+MGY6K/MxC4LHLiiSc6j5UVmzGKp+GsNDXdwOcjDRkyxI2m8gJk449jYNkqZejz1wvwqA/GUt4FcriyxSUYPohuVzL1NOonBLAaS3GKMG3IxPGuX4maV5H6m7ofPGrUqEx6SBdPyNOqVatMHD6vfpAjMq1NV3K9e/dO66KtSfzgvJHDHyYN+QFh3K6s537wQveDba7yL40hsUoVuXPBO+dwxGvrz+rkKz7Ss02IBgk8R3nRIAHycqaneJFGDfsJ4mmaIszzSM87ciSLzXmB1R08XfGqhIpTxCI0Hv9rK7n/r1jUwQsZizp4IWNRBy9kLOrghYok+R+9B5ClWhRdjQAAAABJRU5ErkJggg==" alt="" width="88" height="81" vspace="0" hspace="0" border="0" style="width:88px;height:81px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p></td><td dir="rtl" style="text-align:right; width:411px"><p>الأردن :</p><ul><li dir="rtl">المؤسسة العامة للغذاء والدواء الأردنية</li><li dir="rtl">الموقع الالكتروني : Jfda.com&nbsp;</li><li dir="rtl">البريد الالكتروني : jpc@jfda.jo</li><li dir="rtl">هاتف : 5632000 -6- 926+</li><li dir="rtl">رابط الابلاغ:&nbsp;https://primaryreporting.who.umc.org/JO</li><li dir="rtl">رمز الاستجابة السريع :&nbsp;</li></ul><p><img src="data:image/png;base64,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" alt="" width="79" height="85" vspace="0" hspace="0" border="0" style="width:79px;height:85px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;<p>&nbsp;</p></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In overdoses up to 15 g, no unexpected adverse reactions were reported. In the post-marketing experience, the most commonly reported adverse reactions observed when pregabalin was taken in overdose included somnolence, confusional state, agitation, and restlessness.</p><p>Treatment of pregabalin overdose should include general supportive measures and may include haemodialysis if necessary (see section 4.2 Table 1).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>- Anatomical Therapeutical Chemical (ATC): </strong></p><p>N03AX16.</p><p><strong>- Pharmacotherapeutic group: </strong></p><p>The active substance, pregabalin, is a gamma-aminobutyric acid analogue ((S)-3- (aminomethyl)-5- methylhexanoic acid).</p><p><u>Mechanism of action</u></p><p>Pregabalin binds to an auxiliary subunit (&alpha;2-&delta; protein) of voltage-gated calcium channels in the central nervous system, potently displacing [3H]-gabapentin.</p><p><u>Clinical experience </u></p><p><em>Neuropathic pain</em></p><p>Efficacy has been shown in trials in diabetic neuropathy, post herpetic neuralgia and spinal cord injury. Efficacy has not been studied in other models of neuropathic pain. Pregabalin has been studied in 10 controlled clinical trials of up to 13 weeks with twice a day dosing (BID) and up to 8 weeks with three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar.</p><p>In clinical trials up to 12 weeks for both peripheral and central neuropathic pain, a reduction in pain was seen by week 1 and was maintained throughout the treatment period. In controlled clinical trials in peripheral neuropathic pain 35% of the pregabalin treated patients and 18% of the patients on placebo had a 50% improvement in pain score. For patient&rsquo;s not experiencing somnolence, such an improvement was observed in 33% of patients treated with pregabalin and 18% of patients on placebo. For patients who experienced somnolence the responder rates were 48% on pregabalin and 16% on placebo. In the controlled clinical trial in central neuropathic pain 22% of the Pregabalin treated patients and 7% of the patients on placebo had a 50% improvement in pain score.</p><p>&nbsp;</p><p><em>Epilepsy</em></p><p>Pregabalin has been studied in 3 controlled clinical trials of 12 week duration with either twice a day dosing (BID) or three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar. A reduction in seizure frequency was observed by Week 1.</p><p><em>Paediatric population </em></p><p>The efficacy and safety of pregabalin as adjunctive treatment for epilepsy in paediatric patients below the age of 12 and adolescents has not been established. The adverse events observed in a pharmacokinetic andtolerability study that enrolled patients from 3 months to 16 years of age (n=65) with partial onset seizures were similar to those observed in adults. Results of a 12-week placebo-controlled study of 295 paediatricpatients aged 4 to 16 years and a 14-day placebo-controlled study of 175 paediatric patients aged 1 month to younger than 4 years of age performed to evaluate the efficacy and safety of pregabalin as adjunctivetherapy for the treatment of partial onset seizures and two 1 year open label safety studies in 54 and 431 paediatric patients respectively, from 3 months to 16 years of age with epilepsy indicate that the adverseevents of pyrexia and upper respiratory infections were observed more frequently than in adult studies of patients with epilepsy (see sections 4.2, 4.8 and 5.2).</p><p>In the 12-week placebo-controlled study (4 to 16 years of age), paediatric patients were assigned to pregabalin 2.5 mg/kg/day (maximum, 150 mg/day), pregabalin 10 mg/kg/day (maximum, 600 mg/day), or placebo.The percentage of subjects with at least a 50% reduction in partial onset seizures as compared to baseline was 40.6% of subjects treated with pregabalin 10 mg/kg/day (p=0.0068 versus placebo), 29.1% of subjectstreated with pregabalin 2.5 mg/kg/day (p=0.2600 versus placebo) and 22.6% of those receiving placebo.</p><p>&nbsp;</p><p>In the 14-day placebo-controlled study, paediatric patients (1 month to younger than 4 years of age) were assigned to pregabalin 7 mg/kg/day, pregabalin 14 mg/kg/day, or placebo. Median 24-hour seizurefrequencies at baseline and at the final visit were 4.7 and 3.8 for pregabalin 7 mg/kg/day, 5.4 and 1.4 for pregabalin 14 mg/kg/day, and 2.9 and 2.3 for placebo, respectively. Pregabalin 14 mg/kg/day significantlyreduced the log-transformed partial onset seizure frequency versus placebo (p=0.0223); pregabalin 7 mg/kg/day did not show improvement relative to placebo.</p><p>In a 12-week placebo-controlled study in subjects with Primary Generalized TonicClonic (PGTC) seizures 219 subjects (aged 5 to 65 years, of which 66 were aged 5 to 16 years) were assigned to pregabalin 5mg/kg/day (maximum 300 mg/day), 10 mg/kg/day (maximum 600 mg/day) or placebo as adjunctive therapy. The percentage of subjects with at least a 50% reduction in PGTC seizure rate was 41.3%, 38.9% and41.7% for pregabalin 5 mg/kg/day, pregabalin 10 mg/kg/day and placebo respectively. Monotherapy (newly diagnosed patients)</p><p>Pregabalin has been studied in 1 controlled clinical trial of 56 week duration with BID dosing. Pregabalin did not achieve non-inferiority to lamotrigine based on the 6-month seizure freedom endpoint. Pregabalin andlamotrigine were similarly safe and well tolerated.</p><p>&nbsp;</p><p><em>Generalized Anxiety Disorder </em></p><p>Pregabalin has been studied in 6 controlled trials of 4-6 week duration, an elderly study of 8 week duration and a long-term relapse prevention study with a double blind relapse prevention phase of 6 months duration. Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale (HAM-A) was observed by Week 1.</p><p>In controlled clinical trials (4-8 week duration) 52% of the pregabalin treated patients and 38% of the patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint. In controlled trials, a higher proportion of patients treated with pregabalin reported blurred vision than did patients treated with placebo which resolved in a majority of cases with continued dosing. Ophthalmologic testing (including visual acuity testing, formal visual field testing and dilated funduscopic examination) was conducted in over 3600 patients within controlled clinical trials. In these patients, visual acuity was reduced in 6.5% of patients treated with pregabalin, and 4.8% of placebo-treated patients. Visual field changes were detected in 12.4% of pregabalin-treated, and 11.7% of placebo-treated patients. Funduscopic changes were observed in 1.7% of pregabalin-treated and 2.1% of placebo-treated patients.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with epilepsy receiving anti-epileptic drugs and patients with chronic pain.</p><p><strong>Absorption</strong></p><p>Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma concentrations occurring within 1 hour following both single and multiple dose administration. Pregabalin oral bioavailability is estimated to be &ge;90% and is independent of dose. Following repeated administration, steady state is achieved within 24 to 48 hours. The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25-30% and a delay in tmax to approximately 2.5 hours. However, administration of pregabalin with food has no clinically significant effect on the extent of pregabalin absorption.</p><p><strong>Distribution</strong></p><p>In preclinical studies, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys. Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats. In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.56 l/kg. Pregabalin is not bound to plasma proteins.</p><p><strong>Biotransformation</strong></p><p>Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabelled pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, there was no indication of racemisation of pregabalin S-enantiomer to the Renantiomer.</p><p><strong>Elimination</strong></p><p>Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. Pregabalin mean elimination half-life is 6.3 hours. Pregabalin plasma clearance and renal clearance are directly proportional to creatinine clearance (see section 5.2 Renal impairment). Dose adjustment in patients with reduced renal function or undergoing haemodialysis is necessary (see Section 4.2 Table 1).</p><p>&nbsp;</p><p><strong>Linearity / non-linearity </strong></p><p>Pregabalin pharmacokinetics are linear over the recommended daily dose range. Intersubject pharmacokinetic variability for pregabalin is low (&lt;20%). Multiple dose pharmacokinetics are predictable from single-dose data. Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin.</p><p>&nbsp;</p><p><strong>Pharmacokinetic properties in Special Populations </strong></p><p><u>Gender</u></p><p>Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of pregabalin.</p><p><u>Renal impairment</u></p><p>Pregabalin clearance is directly proportional to creatinine clearance. In addition, pregabalin is effectively removed from plasma by haemodialysis (following a 4 hour haemodialysis treatment plasma pregabalin concentrations are reduced by approximately 50%). Because renal elimination is the major elimination pathway, dose reduction in patients with renal impairment and dose supplementation following haemodialysis is necessary (see section 4.2 Table 1).</p><p><u>Hepatic impairment </u></p><p>No specific pharmacokinetic studies were carried out in patients with impaired liver function. Since pregabalin does not undergo significant metabolism and is excreted predominantly as unchanged drug in the urine, impaired liver function would not be expected to significantly alter pregabalin plasma concentrations.</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p>Pregabalin pharmacokinetics were evaluated in paediatric patients with epilepsy (age groups: 1 to 23 months, 2 to 6 years, 7 to 11 years and 12 to 16 years) at dose levels of 2.5, 5, 10 and 15 mg/kg/day in apharmacokinetic and tolerability study.</p><p>Pregabalin clearance tends to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with decreases in creatinine clearance associated with increasing age. Reduction of pregabalin dose may be required in patients who have age related compromised renal function (see section 4.2 Table 1).</p><p>After oral administration of pregabalin in paediatric patients in the fasted state, in general, time to reach peak plasma concentration was similar across the entire age group and occurred 0.5 hours to 2 hours postdose.</p><p>Pregabalin Cmax and AUC parameters increased in a linear manner with increasing dose within each age group. The AUC was lower by 30% in paediatric patients below a weight of 30 kg due to an increased bodyweight adjusted clearance of 43% for these patients in comparison to patients weighing &ge;30 kg.</p><p>Pregabalin terminal half-life averaged about 3 to 4 hours in paediatric patients up to 6 years of age, and 4 to 6 hours in those 7 years of age and older.</p><p>Population pharmacokinetic analysis showed that creatinine clearance was a significant covariate of pregabalin oral clearance, body weight was a significant covariate of pregabalin apparent oral volume ofdistribution, and these relationships were similar in paediatric and adult patients. Pregabalin pharmacokinetics in patients younger than 3 months old have not been studied (see sections 4.2, 4.8 and 5.1).</p><p><u>Elderly (over 65 years of age)</u></p><p>Pregabalin clearance tends to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with decreases in creatinine clearance associated with increasing age. Reduction of pregabalin dose may be required in patients who have age related compromised renal function (see section 4.2 Table 1).</p><p>&nbsp;</p><p><u>Breast-feeding mothers </u></p><p>The pharmacokinetics of 150 mg pregabalin given every 12 hours (300 mg daily dose) was evaluated in 10 lactating women who were at least 12 weeks postpartum. Lactation had little to no influence on pregabalinpharmacokinetics. Pregabalin was excreted into breast milk with average steady-state concentrations approximately 76% of those in maternal plasma. The estimated infant dose from breast milk (assuming mean milkconsumption of 150 mL/kg/day) of women receiving 300 mg/day or the maximum dose of 600 mg/day would be 0.31 or 0.62 mg/kg/day, respectively. These estimated doses are approximately 7% of the total dailymaternal dose on a mg/kg basis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In conventional safety pharmacology studies in animals, pregabalin was well-tolerated at clinically relevant doses. In repeated dose toxicity studies in rats and monkeys CNS effects were observed, including hypoactivity, hyperactivity and ataxia. An increased incidence of retinal atrophy commonly observed in aged albino rats was seen after long term exposure to pregabalin at exposures &ge;5 times the mean human exposure at the maximum recommended clinical dose. Pregabalin was not teratogenic in mice, rats or rabbits. Fetal toxicity in rats and rabbits occurred only at exposures sufficiently above human exposure. In prenatal/postnatal toxicity&nbsp;studies, pregabalin induced offspring developmental toxicity in rats at exposures&gt;2 times the maximum recommended human exposure. Adverse effects on fertility in male and female rats were only observed at exposures sufficiently in excess of therapeutic exposure.</p><p>Adverse effects on male reproductive organs and sperm parameters were reversible and occurred only at exposures sufficiently in excess of therapeutic exposure or were associated with spontaneous degenerative processes in male reproductive organs in the rat. Therefore the effects were considered of little or no clinical relevance.</p><p>Pregabalin is not genotoxic based on results of a battery of in vitro and in vivo tests. Two-year carcinogenicity studies with pregabalin were conducted in rats and mice. No tumours were observed in rats at exposures up to 24 times the mean human exposure at the maximum recommended clinical dose of 600 mg/day. In mice, no increased incidence of tumours was found at exposures similar to the mean human exposure, but an increased incidence of haemangiosarcoma was observed at higher exposures. The nongenotoxic mechanism of pregabalin-induced tumor formation in mice involves platelet changes and associated endothelial cell proliferation. These platelet changes were not present in rats or in humans based on short term and limited long term clinical data. There is no evidence to suggest an associated risk to humans. In juvenile rats the types of toxicity do not differ qualitatively from those observed in adult rats. However, juvenile rats are more sensitive. At therapeutic exposures, there was evidence of CNS clinical signs of hyperactivity and bruxism and some changes in growth (transient body weight gain suppression). Effects on the estrus cycle were observed at 5-fold the human therapeutic exposure. Reduced acoustic startle response was observed in juvenile rats 1-2 weeks after exposure at&gt;2 times the human therapeutic exposure. Nine weeks after exposure, this effect was no longer observable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Excipients</strong></p><p>- Lactose NF Fast Flow.</p><p>- Starch (1500).</p><p>- Purified Talc.</p><p><strong>Capsule Shell (Body and Cap) Contains of</strong></p><p>- Gelatin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 3 Years/36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&minus;Store below 30oC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>--Clear PVC/PVDC blister strips and aluminium foil</p><p>- Each unit carton contains 30 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>